局部晚期头颈部鳞状细胞癌原发放化疗的生物标志物特征——基于DKTK-ROG多中心队列的假设生成
基于德国癌症联盟放射肿瘤组(DKTK-ROG)回顾性生物标志物研究的多中心队列,对局部晚期头颈部鳞状细胞癌(HNSCC)原发放化疗(RCTx)患者,将既往发现的与局部区域肿瘤控制(LRC)或总生存(OS)显著相关的临床参数和生物标志物通过Cox回归多因素建模组合,定义了三种生物标志物特征用于LRC和OS的患者分层,并将在已完成招募的前瞻性HNprädBio研究中验证。
要点
- 基线特征包含肿瘤体积、p16状态、癌症干细胞标志物CD44表达及缺氧相关基因表达。
- 扩展特征和数据驱动特征额外纳入ERCC2基因rs1799793、ERCC5基因rs17655以及CXCR4、SDF-1和SLC3A2表达。
- 三种特征对LRC和OS均显示显著的患者分层。
核心结论
- 针对接受原发放化疗的局部晚期HNSCC患者,定义了三种用于LRC和OS终点的生物标志物特征,将在前瞻性HNprädBio研究验证后再考虑用于干预性试验。
研究设计与样本
- 基于DKTK-ROG回顾性生物标志物研究的多中心HNSCC队列,对既往发表的分子分析中与LRC或OS显著相关的参数和标志物进行Cox回归多因素建模并采用后退变量选择。
主要发现
- 基线特征包含肿瘤体积、p16状态、癌症干细胞标志物CD44表达和缺氧相关基因表达,代表本研究的主要假设。
- 基线特征经额外预后标志物扩展,并针对两个终点生成无预设假设的数据驱动特征。
- 扩展特征和数据驱动特征中额外纳入ERCC2基因rs1799793、ERCC5基因rs17655以及CXCR4、SDF-1和SLC3A2表达。
- 三种特征对LRC和OS均显示显著的患者分层。
关键数值与推荐
- 基线特征纳入肿瘤体积、p16状态、CD44表达和缺氧相关基因表达。
- 扩展特征和数据驱动特征额外纳入ERCC2基因rs1799793、ERCC5基因rs17655以及CXCR4、SDF-1和SLC3A2表达。
临床怎么用
- 原文未据此给出推荐。
局限性
- 本研究为回顾性生物标志物研究,所定义的特征属于假设生成。
- 三种特征需在已完成招募的前瞻性HNprädBio研究中验证后,才考虑用于干预性试验。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To develop prognostic biomarker signatures for patients with locally advanced head and neck squamous cell carcinoma (HNSCC) treated by primary radiochemotherapy (RCTx) based on previously published molecular analyses of the retrospective biomarker study of the German Cancer Consortium - Radiation Oncology Group (DKTK-ROG). MATERIAL AND METHODS: In previous studies on the retrospective DKTK-ROG HNSCC cohort treated with primary RCTx, the following clinical parameters and biomarkers were evaluated and found to be significantly associated with loco-regional tumour control (LRC) or overall survival (OS): tumour volume, p16 status, expression of cancer stem cell markers CD44 and SLC3A2, expressions of hypoxia-associated gene signatures, tumour mutational burden (TMB), single nucleotide polymorphisms (SNPs) in the ERCC2 gene (rs1799793, rs13181) and ERCC5 gene (rs17655) as well as the expression of CXCR4, SDF-1 and CD8. These biomarkers were combined in multivariable modelling using Cox-regression with backward variable selection. RESULTS: A baseline signature containing the widely accepted parameters tumour volume, p16 status, cancer stem cell marker expression (CD44), and hypoxia-associated gene expression has been defined, representing the main hypothesis of the study. Furthermore, the baseline signature was extended by additional prognostic biomarkers and a data-driven signature without any pre-hypothesis was generated for both endpoints. In these signatures, the SNPs rs1799793 and rs17655 as well as CXCR4, SDF-1 and SLC3A2 expression were additionally included. The signatures showed significant patient stratifications for LRC and OS. CONCLUSION: Three biomarker signatures were defined for patients with locally advanced HNSCC treated with primary RCTx for the endpoints LRC and OS. These signatures will be validated in the prospective HNprädBio study of the DKTK-ROG that recently completed recruitment, before potential application in an interventional trial.
引用
- Löck S, Linge A, Lohaus F, et al. Biomarker signatures for primary radiochemotherapy of locally advanced HNSCC - Hypothesis generation on a multicentre cohort of the DKTK-ROG. Radiother Oncol. 2022. PMID: 35182686. doi:10.1016/j.radonc.2022.02.009
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。